VideoRegulatory Considerations for Long-Acting Anti-Infectives: Challenges and Opportunities - Kellie Schoolar ReynoldsView Video
VideoLong-Acting Antiretroviral Monoclonal Antibodies: Revolutionizing HIV Prevention - Huub GelderblomView Video
VideoGetting It Right This Time: The Impact of PEPFAR Stop Work Orders on Injectable PrEP and Implications for LEN Rollout - Stacey HannahView Video
VideoPharmacokinetic Considerations of Long-Acting Anti-Infective Administration During Pregnancy - Robert BiesView Video
VideoThe Long-Acting Anti-Infective Agents for Children and Adolescents: Are We Nearly There Yet? - Natella RakhmaninaView Video
VideoClinical Development of Long-Acting Formulations for Treatment and Prevention of Tuberculosis - Kimberly ScarsiView Video
VideoLong-Acting Therapies for Emerging Infections: Insights from COVID-19 - Daniel KuritzkesView Video
VideoHIVAbstract #1 Proof-of-Concept Study of Oral VH4004280, a New HIV-1 Capsid Inhibitor – Paul BennView Video
VideoHIVAbstract LB #1 What Do Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine Think About It? - Katerina ChristopoulosView Video
VideoHIVAbstract #2 Utilization and Effectiveness of Cabotegravir + Rilpivirine in People with HIV (PWH) with Viremia at Treatment Initiation - Richard A. ElionView Video
VideoHIVAbstract #3 Novel Ultra-Long-Acting Injectable Formulations of Bictegravir - Xiaohong QiView Video
VideoHIVAbstract #4 Facilitators and Barriers to Long-Acting Injectable Antiretroviral Therapy Uptake among Youth Living with HIV in Cape Town, South Africa: A COM-B Analysis - Sheree SchwartzView Video
VideoHIVAbstract #5 Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV Viral Suppression, Perinatal and Neonatal Outcomes - William ShortView Video
VideoHIVAbstract LB #2 Twice-Yearly Lenacapavir PrEP in Cisgender Gay Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2) - Meredith ClementView Video
VideoNTDTuberculosisAbstract #6 Development of Long-Acting Telacebec (Q203) for Treatment of M. tuberculosis, M. ulcerans and M. leprae - Martina KovarovaView Video
VideoTuberculosisAbstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed MohamedView Video
VideoTuberculosisAbstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan CoxView Video
VideoHIVAbstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan GrieselView Video
VideoHIVTuberculosisViral Hepatitis and Liver DiseaseAbstract #9 LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape - Lobna GaayebView Video
VideoViral Hepatitis and Liver DiseaseAbstract LB #4 Global Perspectives of People Living with Hepatitis B on Long-Acting Antivirals: Survey Results - Yasmin IbrahimView Video
VideoLong-Acting Injectable Formulation of Ivermectin as a New Vector Control Tool to Reduce Malaria Transmission - Quiterie Savary de BeauregardView Video